GlassScriptPhysician profile
Gabrielle Magee
NPI 1619698388
$6,026.99
in general payments reported to CMS, 2019-2025
8 companies · $2,398 in 2025
The $2,398 reported for 2025 was more than what 98% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $317 · 2024: $3,312 · 2025: $2,398.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $3,053 · Food and Beverage: $2,974.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $3,053.49 |
| Food and Beverage | $2,973.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $5,060.60 | 2023-2025 | Total30, Precision7, Dailies Total1 |
| Coopervision INC. | $416.47 | 2023-2025 | Myday Contact Lens, Misight Contact Lens, Clariti Contact Lens |
| Bausch & Lomb Americas INC. | $125.00 | 2025 | Xiidra, Miebo |
| Amgen INC. | $121.73 | 2024 | Tepezza |
| Tarsus Pharmaceuticals, INC. | $121.13 | 2024 | Xdemvy |
| Horizon Therapeutics Plc | $107.77 | 2023 | Tepezza |
| Johnson & Johnson Vision Care, INC. | $46.86 | 2023 | Acuvue |
| Dompe US, INC. | $27.43 | 2024 | Oxervate |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gabrielle Magee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.